Edward J Wyluda Jihua Cheng Todd D Schell Jeremy S Haley Carol Mallon Rogerio I Neves Gavin Robertson Jeffrey Sivik Heath Mackley Giampaolo Talamo Joseph J Drabick
10.1080/15384047.2015.1026507
Cancer Biol Ther
2015;16(5):662-70.
braf inhibitor cbc, complete blood count cr, complete response crp, c-reactive protein ct, computed tomography ctl, cytotoxic lymphocyte ctla-4, cytotoxic t-lymphocyte-associated protein 4 grzb, granzyme b hd, high dose ifn, interferon il-2, interleukin 2 ldh, lactate dehydrogenase m6p, manose 6 phosphate mapk, mitogen-activated protein kinase pathway pd-1, programmed death 1 pdl-1, programmed death ligand 1 pdl-2, programmed death ligand 2 pet, positron emission tomography pr, partial response rt, radiation therapy sle, systemic lupus erythematosus wbc, white blood cell count cytotoxic therapy, immunotherapy, treatment of melanoma interleukin-2 ipilimumab metastatic melanoma
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/25806780/
Antibodies, Monoclonal / therapeutic use Immunotherapy / methods Interleukin-2 / metabolism Melanoma / drug therapy Melanoma / immunology Proto-Oncogene Proteins B-raf / genetics
Antibodies, Monoclonal / therapeutic use Immunotherapy / methods Interleukin-2 / metabolism Melanoma / drug therapy Melanoma / immunology Proto-Oncogene Proteins B-raf / genetics Case Reports Research Support, Non-U.S. Gov't Antibodies, Monoclonal / administration & dosage Female Humans Ipilimumab Male Melanoma / pathology Middle Aged Neoplasm Metastasis Proto-Oncogene Proteins B-raf / metabolism Antibodies, Monoclonal Interleukin-2 Ipilimumab BRAF protein, human Proto-Oncogene Proteins B-raf
PMC4622667
25806780
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy
2015